Led · Grant · May 2026

SPARK Microsystems designs and develops next-generation short-range wireless communication devices using its patented LE-UWB™ technology, targeting consumer, industrial and medical applications. The company emphasizes ultra-low-power, high-speed connectivity with strong interference robustness and very low latency, and its technology supports ranging and positioning as well as data communication. SPARK cites use cases including wearables, peripherals, tags, sensors and other IoT-connected devices. The firm participates in Canada’s FABrIC initiative and is collaborating with Motsai, Bittele Electronics and C2MI for design, prototyping and manufacturing. SPARK was awarded a CAD $1 million FABrIC grant from the Government of Canada to support product development under the IoT Device Challenge. The article does not provide revenue, user, or valuation metrics.

Participated · Grant · Apr 2026

Aspect Biosystems develops bioengineered cellular medicines and bioprinted tissue therapeutics aimed at restoring or supplementing biological functions, targeting serious metabolic and endocrine diseases including diabetes. Its platform integrates AI-powered bioprinting technology, stem cells, hypoimmune cell engineering and advanced biomaterials. The company has announced a partnership with Novo Nordisk to develop curative medicines for diabetes. Recent government funding (CA$79M federal and CA$23.8M provincial) is intended to support expansion, clinical development and biomanufacturing scale-up and to accelerate a path to commercialization. Aspect is positioning to deepen its platform capabilities and move its therapies toward patient impact.

Led · Equity · Jan 2026

Rezycology operates an end-to-end waste-management platform that spans collecting recyclables from informal waste pickers, processing the materials into factory-ready inputs, and offering corporate waste-handling and digital waste-tracking services. Its core product set includes a digital marketplace app that lets collectors log volumes, monitor real-time prices, and receive higher, quality-linked payouts. The company also runs a shared-ownership recycling plant model, ensuring waste-sector workers benefit from downstream value creation. Approximately 3.7 million Indonesian waste collectors and aggregators constitute Rezycology’s target community, who often lack stable earnings and formal protections. By reducing contamination and introducing transparent pricing, the startup helps these workers achieve better margins and steadier income. Beyond its existing operations, Rezycology plans to use fresh capital and technical support to professionalize the waste-collection sector further and scale its impact across Indonesia. The articles did not disclose revenue, user counts, or other operating metrics.

Led · Equity · Aug 2025

Polara is a Québec-based company developing the CHRGPK ("chargepack"), an infrastructure solution for charging medium- and heavy-duty electric vehicles. The firm is working on a CHRGPK 2.0 that adds integrated energy management and vehicle-to-grid (V2G)/vehicle-to-everything capabilities to improve network interaction. The project aims to improve energy efficiency, reduce harmonics from AC-to-DC conversion, and optimize charging speed to protect battery temperature, life, performance and safety. Polara received $1.5 million in government funding to support research, development and demonstration of the upgraded unit. Over a two-year program the team will complete design, programming, assembly and testing, and deploy the CHRGPK 2.0 at a yet-to-be-determined site with at least six stations (3 AC and 3 DC). The funding, announced under the Decarbonizing Road Transport stream of the federal Energy Innovation Program, is intended to accelerate adoption of fleet electrification in Canada.

Led · Equity · Mar 2025

Entos Pharmaceuticals develops genetic medicines using its proprietary, non-viral Fusogenix PLV delivery platform. The Fusogenix PLV platform is formulated with FAST proteins to enable direct fusion delivery of RNA, DNA and gene‑editing therapies and is described as combining the best aspects of viral and non‑viral approaches. Entos says the platform is suitable for a wide range of genetic medicines and is committed to advancing next‑generation therapies to improve patients' lives. The company will use CureDuchenne Ventures' initial $1M investment to create a muscle‑targeting therapeutic to deliver full‑length dystrophin for Duchenne muscular dystrophy (DMD). Entos plans to share information about the platform and its Duchenne program at the CureDuchenne 2025 FUTURES National Conference. Entos was founded in 2016 and is headquartered in Edmonton, Canada, with wholly owned U.S. and U.K. subsidiaries in San Diego and London. Entos Pharmaceuticals develops next-generation nucleic acid therapeutics using its proprietary Fusogenix PLV proteolipid vehicle platform. The Fusogenix PLV system uses FAST proteins to enable direct fusion delivery of nucleic acids to target cells. Entos plans to build a 103,000-square-foot R&D centre and a GMP biomanufacturing facility in Edmonton to develop, scale up, produce, and commercialize Fusogenix PLV therapeutics. The $198.5 million project is supported by $77.5 million in government funding. Entos has partnerships with Eli Lilly and collaborators including Oisin Biotechnologies, OncoSenX, and Aegis Life and aims to foster academic and industry collaborations in Canada. The company was founded in 2016 and is headquartered in Edmonton, with U.S. and U.K. subsidiaries in San Diego and London. Entos Pharmaceuticals is a clinical-stage genetic medicines company that uses its proprietary Fusogenix PLV platform to deliver RNA, DNA, and gene‑editing therapies. Its lead program, ENTLEP001, is a systemically administered investigational gene therapy designed to express native human leptin for the treatment of congenital generalized lipodystrophy (CGL); the candidate is intended to be durable and redosable. Preclinical studies in a leptin‑deficient mouse model produced clinically relevant leptin expression, normalization of glucose and insulin levels, and reduced weight gain and food intake. The company says the Fusogenix PLV platform combines aspects of viral and non‑viral approaches and published animal safety, efficacy, and biodistribution data in Cell in September 2024. Entos has stated plans to advance a second product into the clinic and has partnered with global companies including Eli Lilly. The company was founded in 2016 and is headquartered in Edmonton, Canada, with U.S. and U.K. subsidiaries in San Diego and London.